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REPORTS on cortisone's effect on the growth of transplantable tumours are
numerous, as are the conclusions reached and the theories advanced in explana-
tion. The results range from inhibition of tumour growth (Burchenal, Stock and
Rhoads, 1950; Baserga and Shubik, 1954; Goldie et al., 1954; Sparck, 1962) to
enhancement (Green and Whiteley, 1952 ; Toolan, 1953).
In the course of a preliminary experiment it was noticed that although corti-
sone supressed the intraperitoneal growth of Ehrlich's ascites carcinoma, sub-
cutaneous growth of the tumour back along the needle track in the same mouse
was enhanced (Table I). The present study seeks to establish and explain this
dual action of cortisone on the growth of the Ehrlich ascites carcinoma, which is
a homotransplantable mouse mammary carcinoma of undefined genetic origin.
TABLE I.-Intraperitoneal and Subcutaneous Growth ofEhrlich's Ascites Carcinoma
in Untreated Mice, and in Mice Treated With Cortisone (25 mg./kg. Starting
weight, Daily, Subcutaneously) From 6 Days Before Transplantation. (30
Mice in Each Group.)
Mean volume Subcutaneous tumour growth
of tumour back along needle track in
ascites at 8-day survivors
death of , -
Treatment mouse (ml.) Visible Palpable Absent
Nil . 659 . 10 7 7
Cortisone . 120 . 27 0 0
MATERIAL AND METHODS
The mice came from the closed colony kept at this Institute (Hartveit, 1961).
The Ehrlich ascites carcinoma was injected both subcutaneously and intraperi-
toneally. Cortisone acetate suspension was diluted 1 in 12 in physiological
saline and used for both subcutaneous and intraperitoneal injections. Saline
was used for control injections.
Tumour cells from an 11 day transplant in a male mouse were used. The
tumour dosage was 0 1 ml. whole tumour ascites per mouse. The cortisone
dosage was equivalent to 25 mg. per kg. starting weight. The cortisone and
corresponding saline injections were given daily for 10 days with the exception
ofday 3. On day 5 tumour or corresponding saline injections were given.
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Experimental procedure
Experiment I. Intraperitoneal tumour yrowth.-Two groups of 15 male and
15 female mice were set up (mean weight ± S.D. in each group, & = 29.2 +
1.0 g., y = 24-3 ± 1.0 g.). Both groups were given tumour intraperitoneally.
Group 1 was given saline and group 2 cortisone, subcutaneously, as described
above.
On day 11 all the mice were killed. The volume of tumour ascites was
measured, the packed cell volume (PCV) of the tumour cells determined, and,
where necessary, the PCV of the erythrocytes subtracted from the total PCV.
From these figures the total fluid volume per g. mouse and the total tumour
cell volume were calculated.
Experiment II. Subcutaneous tumour growth.-(a) The procedure was identi-
cal to that in experiment I except that the tumour was given subcutaneotusly
and the saline or cortisone intraperitoneally (groups 1 and 2, respectively). (b)
This consisted of two groups (3 and 4) of 15 female mice (mean weight + S.D.
26-4 i 2.2 g.). The tumour was given subcutaneously to both groups. Cortis-
one was given intraperitoneally. The dosage in group 3 was as in group 2, while
group 4 were given double this dosage.
On day 11 all the mice were killed. The skin and tumours were removed
and fixed in formalin. The next day the tumours were measured, using the sum
of the two greatest diameters at right angles.
RESULTS
Experiment I. Intraperitoneal tumour growth.
Mean intraperitoneal fluid volume.-This was greatest in group 1 in which
the sex difference was not statistically significant (0-1>P>0.05). In group 2
the volume was significantly greater in the females than in the males (0.001>P).
For both sexes the volume in group 2 was significantly less than that in group 1
(0.001>P).
Mean total tumour cell volume.-This was greatest in group 1 in which the sex
difference was not significant (0*4>P>0-3). In group 2 the volume in the
females was greater than that in the males (0.001>P). Comparing groups 1
and 2 there was significantly less tumour in both sexes in group 2 (0-001>P).
Mean PCV of tumour cells.-In group 1 this was significantly higher in the
females than in the males (0.001>P). In both the lower values in group 1
compared to group 2 are significant (0.001>P).
Experiment II. Subcutaneous tumour growth.
In groups 1 and 2 the mean tumour diameter was significantly greater in the
males than in the females (0.001>P). There were no significant differences
between the diameters in the females in groups 1, 2 and 3, but the diameter in
group 4 was significantly greater than that in the other groups (0.001>P). The
diameter in the males in group 1 was significantly less than that in the males
in group 2 (0-02>P>0.01).
DISCUSSION
The present experiments confirm the dual action of cortisone on the growth
of Ehrlich's ascites carcinoma. Intraperitoneal tumour growth was inhibited
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TABLE II.-Cortisone's Effect on the Intraperitoneal (I.P.) Growth of Ehrlich's




Mean IP fluid 3 15 43 . 065
vol./g. mouse 9 12-30 . 3-85
(1/100 ml.)
Mean total tum- l . 1590 . 13.0
our vol., pack- ? 174 0 . 67*0
ed cells (1/100
ml.)
Mean PCV of c . 22*4 . 420
tumour 9 . 35.3 . 43 2
cells (%)
* 1, and 1I mouse died before the close of the experiment.
tresults based on 7&3 and 13? mice as too little fluid available to investigate in the others.
TABLE III.-Cortisone's Effect on the Subcutaneous Growth of Ehrlich's Ascites
Carcinoma. (15 CT and 15 V Mice in Groups 1 and 2, 15 Y Mice in 3 and 4.)
Treatment Saline Cortisone Saline Cortisone
(intraperitoneal) x 2 x 2
Group 1* 2t 3 4$
Mean tumour c . 30 5 35-6
diameter§ (mm.) y 23-6 25 8 . 25-6 33-8
*4 males )
t 3 males . died before the close of the experiment.
I I female J
§ see text.
in cortisone treated mice, whilst subcutaneous growth of the same tumour was
enhanced by cortisone treatment. This dual effect speaks against the view
that cortisone has any direct action on the tumour cells used here. Thus it
probably acts through the host's response to the homografted tumour cells.
It has previously been shown that such tumour cells are sensitised, i.e. anti-
body coated (Hartveit, 1965a) andthey have been shownto lyse onintraperitoneal
transplantation (Hartveit, 1963) or in the presence of complement in a medium
of low protein content (Hartveit, 1965a). Thus the host response to the injection
of this tumour can take two main forms. The first, the specific inflammatory
response to the products of lysis of sensitised tumour cells (primary lysis) leads
to the formation of an inflammatory exudate. This exudate, i.e. the ascitic
fluid that forms following intraperitoneal injection, has been shown to contain
an inhibitor of immunological lysis (Hartveit, 1964). Once this inhibitor is
present immunological lysis is no longer seen in vivo (Hartveit, 1963). Thus it
is probable that its presence, that leads to a state of immunological tolerance,
explains the progressive growth of this homograft.
However, the presence of inhibitor does not prevent the continued sensitisa-
tion of the tumour cells, as sensitisation has been shown to increase with time
followingtransplantation (Hartveit, 1965b). Thus sensitisation ofnew generations
of tumour cells is the second type of response to this tumour.
Cortisone can be expected to depress both these responses; the first via its
effect on capillary permeability; the second:via its effect on the reticuloendothelial
system.
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On intraperitoneal transplantation in cortisone treated mice primary lysis
should not be affected, but the inflammatory response that normally follows this
this should be reduced. The cells that survive primary lysis will give rise to new
generations of unsensitised cells. Then if the cortisone dosage allows complete
inhibition of the recipient's immune response these cells will grow unhindered.
Ifthe immune response is not completelyabolishedthe cells will become sensitised,
secondary lysis will become possible and a balance will be set up between antibody,
complement and inhibitor that will determine the extent of tumour growth.
Ifthe culminative effect ofprimary and secondary lysis were more than the corti-
sone dosage could combat, exudate formation could occur, giving some degree
of tolerance and hence an increase in tumour growth.
Consequently one would expect intraperitoneal tumour growth to be less than
in normal controls; the final result, on low cortisone dosage, being as dependent
on cortisone's action on the recipient's immune response as on its action on capil-
lary permeability.
The present experiments showed that treatment with cortisone decreased
the intraperitoneal fluid volume and the total tumour volume in both sexes as
expected theoretically. The fluid volume and tumour volume were greater
in female mice treated with cortisone than in males, while the sex difference
in the saline treated mice was not significant. If we follow the above reasoning
this suggests that the immune response of the females was greater than that of
the males. This is seconded by the previous finding that the survival time after
subcutaneous transplantation is almost twice as long in females as in males
(Hartveit, 1962). In this connection Halpern's (1964) observation that the
immune response to bacterial stimuli is greater in female mice may be pertinent.
Goldie et al. (1954) have suggested that lack of exudate formation in cortisone
treated mice hinders tumour growth by interfering with the nutrition of the cells.
This is unlikely to be the case here as, in spite ofthe difference in tumour growth,
the sex difference in packed cell volume was not significant.
On subcutaneous transplantation into normal mice the inhibitor-rich fluid
injected with the tumour cells will not be dispersed as on intraperitoneal trans-
plantation. So the protective effect of the inhibitor will, to some extent, be in
operation from the start. Less primary lysis will then be possible and less
inhibitor-rich exudate will be formed. In time the inhibitor injected originally
with the cells will be used up or dispersed. The new tumour cells produced will
be unsensitised at first, but will become progressively sensitised due to the host's
immune response. Thus tumour growth will depend on a balance between
antibody, complement and inhibitor, as with cortisone treated intraperitoneal
tumour.
In cortisone treated mice subcutaneous tumour growth should progress as in
untreated animals until the host's immune response comes into the picture. In
these animals the new cells produced will remain unsensitised if the cortisone
dosage allows complete inhibition of the recipient's immune response-and these
cells will grow unhindered. Consequently one would expect subcutaneous tumour
growth to be increased by cortisone treatment. However, if this response were
not completely abolished a balance would be set up as in untreated animals,
and this could lead to some inhibition of tumour growth.
The present experiments show that tumour growth was increased in cortisone
treated male mice, but that such treatment had no effect on tumour growth in
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females. If, as suggested above, we postulate that the females' immune response
was greater than that of the males, the possibility that the cortisone dosage was
not great enough to overcome it arises. This is probably the case as the present
experiments showed that an increase in tumour growth in females could be ob-
tained by doubling the cortisone dosage.
SUMMARY
Cortisone is shown to decrease the intraperitoneal growth of Ehrlich's ascites
carcinoma and to increase the subcutaneous growth ofthe same tumour.
I would like to thank Professor E. Waaler for the interest he has shown in this
work.
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